Trevi Therapeutics, Inc. announced that it has entered into a definitive agreement with a healthcare-focused institutional investor, for the purchase, in a private placement priced at-the-market under Nasdaq rules, of 2,373,201 shares of common stock and accompanying warrants to purchase an aggregate of 4,746,402 shares of common stock.
September 30, 2021
· 7 min read